Applied Therapeutics Inc.
0.64
-0.05 (-7.38%)
At close: Jan 14, 2025, 3:59 PM
0.66
3.06%
Pre-market Jan 15, 2025, 06:49 AM EST
undefined%
Bid 0.64
Market Cap 74.43M
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.42
PE Ratio (ttm) -0.45
Forward PE n/a
Analyst Hold
Ask 0.67
Volume 8,142,045
Avg. Volume (20D) 6,288,604
Open 0.70
Previous Close 0.69
Day's Range 0.62 - 0.73
52-Week Range 0.60 - 10.62
Beta undefined

About APLT

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel products to target cardiovascular disease, galactosemia, and diabetic complications. Its lead product candidate is AT-007 that has completed phase 1/2 for the treatment of galactosemia in healthy volunteers and adults, as well as is in pediatric clinical study for the treatment of galactosemia in kids; for treating sorbitol dehydrogenase deficiency; and for the...

Industry Biotechnology
Sector Healthcare
IPO Date May 14, 2019
Employees 37
Stock Exchange NASDAQ
Ticker Symbol APLT

Analyst Forecast

According to 6 analyst ratings, the average rating for APLT stock is "Hold." The 12-month stock price forecast is $5, which is an increase of 681.62% from the latest price.

Buy 50.00%
Hold 50.00%
Sell 0.00%
Stock Forecasts

Next Earnings Release

Applied Therapeutics Inc. is scheduled to release its earnings on Mar 5, 2025, before market opens.
Analysts project revenue of $183.33K, reflecting a -127.49% YoY shrinking and earnings per share of -0.17, making a -57.50% decrease YoY.
3 weeks ago · Source
-13.72%
Applied Therapeutics shares are trading lower afte... Unlock content with Pro Subscription
1 month ago · Source
-13.79%
Applied Therapeutics shares are trading lower after UBS downgraded the stock from Buy to Neutral and cut its price target from $13 to $2.